 |
N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide |
|---|---|
| Trade Name | |
| Orphan Indication | Duchenne muscular dystrophy |
| USA Market Approval | USA |
| USA Designation Date | 2014-11-17 00:00:00 |
| Sponsor | Catabasis Pharmaceuticals, Inc.;One Kendall Square, Suite B14202, Suite B14202;Cambridge, Massachusetts, 02139 |
